{"id":533759,"date":"2021-09-02T08:04:30","date_gmt":"2021-09-02T12:04:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/"},"modified":"2021-09-02T08:04:30","modified_gmt":"2021-09-02T12:04:30","slug":"regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/","title":{"rendered":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment<\/b><\/p>\n<p>HONG KONG&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegencell Bioscience Holdings Limited (NASDAQ: RGC) (\u201cRegencell\u201d or the \u201cCompany\u201d), today announced that Regencell Bioscience Limited (\u201cRegencell HK\u201d), the Company\u2019s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited (\u201cHonor Epic\u201d). The joint venture (\u201cJV\u201d) is expected to offer COVID-19 (\u201cCOVID\u201d) related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.\n<\/p>\n<p>\nAs COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since March 2020, Mr. Sik-Kee Au, Regencell\u2019s strategic partner TCM practitioner, started to develop a Traditional Chinese Medicine treatment formula targeting COVID patients. So far, 12 patients (suspected or confirmed COVID cases) have been treated, and their health records showed improvements after an average treatment period of 5 days.\n<\/p>\n<p>\nRegencell HK and Honor Epic plan to work together to make this treatment available in the ASEAN countries, India, Japan, Australia and New Zealand. Regencell will own 60% of the JV with customary drag-along option. The principal business of the JV shall be to trade, manufacture, market and distribute TCM formulae products, procure, enable, provide or support the treatment of COVID using TCM in the ASEAN countries, India, Japan, Australia and New Zealand.\n<\/p>\n<p>\nYat-Gai Au, Regencell\u2019s Chairman &amp; CEO noted, \u201cWhile the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID. With Mr. Ji Yang Lee\u2019s strong business relationships and extensive network in over 60 countries, we believe that together we will be able to have a positive impact in the fight against COVID.\u201d\n<\/p>\n<p>\nJi Yang Lee, Founder of Honor Epic, noted, \u201cI fully support and echo Regencell\u2019s efforts and primary goal of saving lives. I found a partner that shares the same values and look forward to closely working together with Regencell\u2019s team to quickly bring this treatment directly to patients in need.\u201d\n<\/p>\n<p>\nThe research of JV in COVID treatment is highly uncertain and Regencell cannot guarantee timing of completion of this research and commercialization of COVID treatment in any countries. Regencell will be posting updates regarding treatments in the fight against COVID on its website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.regencellbioscience.com%2F&amp;esheet=52485639&amp;newsitemid=20210902005415&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.regencellbioscience.com%2F&amp;index=1&amp;md5=d99e7904926532f537615e1b7c9897be\">https:\/\/www.regencellbioscience.com\/<\/a> soon.\n<\/p>\n<p><b>About Regencell Bioscience Holdings Limited <\/b><\/p>\n<p>\nRegencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people\u2019s immune system such as COVID. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. Its TCM formulae for the treatment of COVID will be first available in Asia through a joint venture.\n<\/p>\n<p><b>About Honor Epic Enterprises Limited<\/b><\/p>\n<p>\nHonor Epic Enterprises Limited (\u201cHonor Epic\u201d), is an entity controlled by Mr. Ji Yang Lee, who is the Deputy CEO at SKS Worldwide, a leading design, consultancy and manufacturing company provide customized furniture to furnishing hotels, hospitals and corporate workspaces, to offering consulting and business development strategies to Fortune 500 companies, with more than 47 years of operation and extensive business network in over 60 countries.\n<\/p>\n<p><b><i>Forward-Looking Statements<\/i><\/b><\/p>\n<p><i>All statements other than statements of historical fact in this announcement are forward-looking statements.<\/i><i>Such forward-looking statements include the business plan of the joint venture, objectives, expectations and intentions of the joint venture parties, and Regencell\u2019s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. Investors can identify these forward-looking statements by words or phrases such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to\u201d or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty about the spread of the COVID-19 virus and the impact it will have on expected operations of the joint venture, the demand for the planned COVID TCM treatments. These and other risks and uncertainties are detailed in the other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by Regencell.<\/i><\/p>\n<p><i>Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company\u2019s registration statement and in its other filings with the SEC.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210902005415\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210902005415\/en\/<\/a><\/span><\/p>\n<p><b>Corporate:<br \/>\n<\/b><br \/>James Chung<br \/>\n<br \/>COO &amp; CSO<br \/>\n<br \/>Regencell Bioscience Holdings Limited<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@rgcbio.com\">ir@rgcbio.com<\/a><\/p>\n<p><b>Investors outside of Asia Region:<br \/>\n<\/b><br \/>Lena Cati<br \/>\n<br \/>The Equity Group Inc.<br \/>\n<br \/>Vice President<br \/>\n<br \/>(212) 836-9611<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lcati@equityny.com\">lcati@equityny.com<\/a><\/p>\n<p><b>Investors in Asia Region:<br \/>\n<\/b><br \/>Strategic Financial Relations Limited<br \/>\n<br \/>Vicky Lee (852) 2864 4834<br \/>\n<br \/>Brigid Lee (852) 2114 4313<br \/>\n<br \/>Yvonne Lee (852) 2864 4847<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:SPRG_Regencell@sprg.com.hk\">SPRG_Regencell@sprg.com.hk<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Asia Pacific Hong Kong<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases General Health Research Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210902005415\/en\/1151365\/3\/REGENCELL_A_Logo.PNG.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment HONG KONG&#8211;(BUSINESS WIRE)&#8211; Regencell Bioscience Holdings Limited (NASDAQ: RGC) (\u201cRegencell\u201d or the \u201cCompany\u201d), today announced that Regencell Bioscience Limited (\u201cRegencell HK\u201d), the Company\u2019s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited (\u201cHonor Epic\u201d). The joint venture (\u201cJV\u201d) is expected to offer COVID-19 (\u201cCOVID\u201d) related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. As COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since March 2020, Mr. Sik-Kee Au, Regencell\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533759","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment HONG KONG&#8211;(BUSINESS WIRE)&#8211; Regencell Bioscience Holdings Limited (NASDAQ: RGC) (\u201cRegencell\u201d or the \u201cCompany\u201d), today announced that Regencell Bioscience Limited (\u201cRegencell HK\u201d), the Company\u2019s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited (\u201cHonor Epic\u201d). The joint venture (\u201cJV\u201d) is expected to offer COVID-19 (\u201cCOVID\u201d) related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. As COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since March 2020, Mr. Sik-Kee Au, Regencell\u2019s &hellip; Continue reading &quot;Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T12:04:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment\",\"datePublished\":\"2021-09-02T12:04:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/\"},\"wordCount\":984,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/\",\"name\":\"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-09-02T12:04:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment - Market Newsdesk","og_description":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment HONG KONG&#8211;(BUSINESS WIRE)&#8211; Regencell Bioscience Holdings Limited (NASDAQ: RGC) (\u201cRegencell\u201d or the \u201cCompany\u201d), today announced that Regencell Bioscience Limited (\u201cRegencell HK\u201d), the Company\u2019s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited (\u201cHonor Epic\u201d). The joint venture (\u201cJV\u201d) is expected to offer COVID-19 (\u201cCOVID\u201d) related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. As COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since March 2020, Mr. Sik-Kee Au, Regencell\u2019s &hellip; Continue reading \"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T12:04:30+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment","datePublished":"2021-09-02T12:04:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/"},"wordCount":984,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/","name":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-09-02T12:04:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210902005415r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regencell-bioscience-holdings-limited-establishes-a-joint-venture-to-offer-covid-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533759"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533759\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}